✦ LIBER ✦
400 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ
✍ Scribed by M. Gordon; S. Sharma; L. Miller; N. Srinivas; M. Sahu; R. Govindarajan; R. Mullangi; M. Velleca; D. Brittelli
- Book ID
- 119603083
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 47 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.